NovaBridge Biosciences
NBP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,294 | $777 | $6,030 | $4,475 |
| G&A Expenses | $3,820 | $4,489 | $7,341 | $7,937 |
| SG&A Expenses | $3,820 | $4,489 | $7,341 | $7,937 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,114 | $5,266 | $13,371 | $12,412 |
| Operating Income | -$7,114 | -$5,266 | -$13,371 | -$12,412 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,610 | $2,116 | $2,527 | -$8,079 |
| Pre-Tax Income | -$5,504 | -$3,150 | -$10,844 | -$20,491 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,504 | -$3,150 | -$9,062 | -$20,491 |
| % Margin | – | – | – | – |
| EPS | -0.069 | -0.28 | -0.11 | -0.25 |
| % Growth | 75.4% | -154.5% | 56% | – |
| EPS Diluted | -0.069 | -0.28 | -0.11 | -0.25 |
| Weighted Avg Shares Out | 81,699 | 81,600 | 81,496 | 81,496 |
| Weighted Avg Shares Out Dil | 81,699 | 81,600 | 81,496 | 81,496 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,800 | $1,872 | $2,197 | $2,449 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $5,990 |
| EBITDA | -$7,114 | -$5,266 | -$12,098 | -$6,422 |
| % Margin | – | – | – | – |